
CLEOCIN PHOSPHATE[®] (clindamycin injection, USP)

To reduce the development of drug-resistant bacteria and maintain the effectiveness of CLEOCIN PHOSPHATE and other antibacterial drugs, CLEOCIN PHOSPHATE should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.

Sterile Solution is for Intramuscular and Intravenous Use

WARNING

Clostridioides difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including CLEOCIN PHOSPHATE and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of *C. difficile*.

Because CLEOCIN PHOSPHATE therapy has been associated with severe colitis which may end fatally, it should be reserved for serious infections where less toxic antimicrobial agents are inappropriate, as described in the **INDICATIONS AND USAGE** section. It should not be used in patients with nonbacterial infections such as most upper respiratory tract infections.

C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of *C. difficile* cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.

If CDAD is suspected or confirmed, ongoing antibiotic use not directed against *C. difficile* may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of *C. difficile*, and surgical evaluation should be instituted as clinically indicated.


DESCRIPTION

CLEOCIN PHOSPHATE Sterile Solution in vials contains clindamycin phosphate, a water soluble ester of clindamycin and phosphoric acid. Each mL contains the equivalent of 150 mg clindamycin, 0.5 mg disodium edetate and 9.45 mg benzyl alcohol added as preservative in each mL. Clindamycin is a semisynthetic antibiotic produced by a 7(S)chloro-substitution of the 7(R)-hydroxyl group of the parent compound lincomycin.

The chemical name of clindamycin phosphate is L-*threo*-α-D-*galacto*-Octopyranoside, methyl-7-chloro-6,7,8-trideoxy-6-[[(1-methyl-4-propyl-2-pyrrolidinyl)carbonyl] amino]-1-

thio-, 2-(dihydrogen phosphate), (2*S*-trans)-.

The molecular formula is $C_{18}H_{34}CIN_2O_8PS$ and the molecular weight is 504.96. The structural formula is represented below:



CLINICAL PHARMACOLOGY

Distribution

Biologically inactive clindamycin phosphate is converted to active clindamycin. By the end of short-term intravenous infusion, peak serum concentrations of active clindamycin are reached.

After intramuscular injection of clindamycin phosphate, peak concentrations of active clindamycin are reached within 3 hours in adults and 1 hour in pediatric patients.

Serum concentrations of clindamycin can be maintained above the in vitro minimum inhibitory concentrations for most indicated organisms by administration of clindamycin phosphate every 8 to 12 hours in adults and every 6 to 8 hours in pediatric patients, or by continuous intravenous infusion. An equilibrium state is reached by the third dose.

No significant concentrations of clindamycin are attained in the cerebrospinal fluid even in the presence of inflamed meninges.

Metabolism

In vitro studies in human liver and intestinal microsomes indicated that clindamycin is predominantly metabolized by Cytochrome P450 3A4 (CYP3A4), with minor contribution from CYP3A5, to form clindamycin sulfoxide and a minor metabolite, N-desmethylclindamycin.

Excretion

Biologically inactive clindamycin phosphate disappears from the serum with 6 minutes of the average elimination half-life; however, the average serum elimination half-life of active clindamycin is about 3 hours in adults and $2\frac{1}{2}$ hours in pediatric patients.

Specific Populations

Patients with Renal/Hepatic Impairment

The elimination half-life of clindamycin is increased slightly in patients with markedly reduced renal or hepatic function. Hemodialysis and peritoneal dialysis are not effective in removing clindamycin from the serum. Dosage schedules do not need to be modified in patients with renal or hepatic disease.

Geriatric Patients

Pharmacokinetic studies in elderly volunteers (61–79 years) and younger adults (18–39 years) indicate that age alone does not alter clindamycin pharmacokinetics (clearance, elimination half-life, volume of distribution, and area under the serum concentration-time curve) after IV administration of clindamycin phosphate. After oral administration of clindamycin hydrochloride, the average elimination half-life is increased to approximately 4.0 hours (range 3.4–5.1 h) in the elderly, compared to 3.2 hours (range 2.1–4.2 h) in younger adults. The extent of absorption, however, is not different between age groups and no dosage alteration is necessary for the elderly with normal hepatic function and normal (age-adjusted) renal function¹.

Pharmacokinetics in Pediatric Patients with PMA ≤32 weeks, or >32 to ≤40 weeks

Systemic clearance (CL) in premature infants increases with increases in body weight (kg) and post-menstrual age (PMA). The dosing regimens for pediatric patients \leq 32 weeks PMA (5 mg/kg) and >32 to \leq 40 weeks PMA (7 mg/kg), both administered intravenously every 8 hours, achieve exposures comparable to therapeutic exposures in adults (weighing 70 kg) administered clindamycin 600 mg every 8 hours (Table 1).

Table 1: Predicted Drug Exposure (Mean \pm SD) of Clindamycin in Adults and in
Pediatric Patients with PMA ≤32 weeks, or >32 to ≤40 weeks

Age	Adult (70 kg)	PMA ≤32 weeks	PMA>32 - ≤40 weeks
Dose (every 8 hours)	600 mg	5 mg/kg	7 mg/kg
AUC _{ss,0-8 hour} (mcg·h/mL)	50.5 (30.95)	52.5 (17.0)	55.9 (23.55)
C _{max,ss} (mcg/mL)	12.0 (3.49)	9.0 (2.02)	10.5 (2.79)
C _{min,ss} (mcg/mL)	3.1 (3.34)	4.6 (2.00)	4.4 (2.77)

PMA: post-menstrual age; AUC_{ss,0-8 hour}: area under the concentration-time curve during a dosing interval at steady state; $C_{max,ss}$: maximum drug concentration at steady state; $C_{min,ss}$: minimum or trough drug concentration at steady state.

Obese Pediatric Patients Aged 2 to Less than 18 Years and Obese Adults Aged 18 to 20 Years

An analysis of pharmacokinetic data in obese pediatric patients aged 2 to less than 18 years and obese adults aged 18 to 20 years demonstrated that clindamycin clearance and volume of distribution, normalized by total body weight, are comparable regardless of obesity.

Microbiology

Mechanism of Action

Clindamycin inhibits bacterial protein synthesis by binding to the 23S RNA of the 50S subunit of the ribosome. Clindamycin is bacteriostatic.

Resistance

Resistance to clindamycin is most often caused by modification of specific bases of the 23S ribosomal RNA. Cross-resistance between clindamycin and lincomycin is complete. Because the binding sites for these antibacterial drugs overlap, cross-resistance is sometimes observed among lincosamides, macrolides and streptogramin B. Macrolide-inducible resistance to clindamycin occurs in some isolates of macrolide-resistant bacteria. Macrolide-resistant isolates of staphylococci and beta-hemolytic streptococci should be screened for induction of clindamycin resistance using the D-zone test.

Antimicrobial Activity

Clindamycin has been shown to be active against most of the isolates of the following microorganisms, both in vitro and in clinical infections (see **INDICATIONS AND USAGE**):

Gram-positive bacteria

Staphylococcus aureus (methicillin-susceptible strains) *Streptococcus pneumoniae* (penicillin-susceptible strains) *Streptococcus pyogenes*

Anaerobic bacteria

Clostridium perfringens Fusobacterium necrophorum Fusobacterium nucleatum Peptostreptococcus anaerobius Prevotella melaninogenica

The following *in vitro* data are available, but their clinical significance is unknown. At least 90 percent of the following bacteria exhibit an *in vitro* minimum inhibitory concentration (MIC) less than or equal to the susceptible breakpoint for clindamycin against isolates of a similar genus or organism group. However, the efficacy of clindamycin in treating clinical infections due to these bacteria has not been established in adequate and well-controlled clinical trials.

Gram-positive bacteria

Staphylococcus epidermidis (methicillin-susceptible strains) Streptococcus agalactiae Streptococcus anginosus Streptococcus mitis Streptococcus oralis

Anaerobic bacteria

Actinomyces israelii Clostridium clostridioforme Eggerthella lenta Finegoldia (Peptostreptococcus) magna Micromonas (Peptostreptococcus) micros Prevotella bivia Prevotella intermedia Cutibacterium acnes

Susceptibility Testing

For specific information regarding susceptibility test interpretive criteria and associated test methods and quality control standards recognized by FDA for this drug, please see: https://www.fda.gov/STIC.

INDICATIONS AND USAGE

CLEOCIN PHOSPHATE products are indicated in the treatment of serious infections caused by susceptible anaerobic bacteria.

CLEOCIN PHOSPHATE products are also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of antibioticassociated pseudomembranous colitis, as described in the **BOXED WARNING**, before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin).

Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin.

Indicated surgical procedures should be performed in conjunction with antibiotic therapy.

CLEOCIN PHOSPHATE is indicated in the treatment of serious infections caused by susceptible strains of the designated organisms in the conditions listed below:

Lower respiratory tract infections including pneumonia, empyema, and lung abscess caused by anaerobes, *Streptococcus pneumoniae*, other streptococci (except *E. faecalis*), and *Staphylococcus aureus*.

Skin and skin structure infections caused by *Streptococcus pyogenes, Staphylococcus aureus*, and anaerobes.

Gynecological infections including endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection caused by susceptible anaerobes.

Intra-abdominal infections including peritonitis and intra-abdominal abscess caused by susceptible anaerobic organisms.

Septicemia caused by *Staphylococcus aureus*, streptococci (except *Enterococcus faecalis*), and susceptible anaerobes.

Bone and joint infections including acute hematogenous osteomyelitis caused by *Staphylococcus aureus* and as adjunctive therapy in the surgical treatment of chronic

bone and joint infections due to susceptible organisms.

To reduce the development of drug-resistant bacteria and maintain the effectiveness of CLEOCIN PHOSPHATE and other antibacterial drugs, CLEOCIN PHOSPHATE should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

CONTRAINDICATIONS

This drug is contraindicated in individuals with a history of hypersensitivity to preparations containing clindamycin or lincomycin.

WARNINGS

See **BOXED WARNING**.

Clostridioides difficile-Associated Diarrhea

Clostridioides difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including CLEOCIN PHOSPHATE, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of *C. difficile*.

C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of *C. difficile* cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.

If CDAD is suspected or confirmed, ongoing antibiotic use not directed against *C. difficile* may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of *C. difficile*, and surgical evaluation should be instituted as clinically indicated.

Anaphylactic and Severe Hypersensitivity Reactions

Anaphylactic shock and anaphylactic reactions have been reported (see **ADVERSE REACTIONS**).

Severe hypersensitivity reactions, including severe skin reactions such as toxic epidermal necrolysis (TEN), drug reaction with eosinophilia and systemic symptoms (DRESS), and Stevens-Johnson syndrome (SJS), some with fatal outcome, have been reported (see **ADVERSE REACTIONS**).

In case of such an anaphylactic or severe hypersensitivity reaction, discontinue treatment permanently and institute appropriate therapy.

A careful inquiry should be made concerning previous sensitivities to drugs and other allergens.

Benzyl Alcohol Toxicity in Neonates ("Gasping Syndrome")

This product contains benzyl alcohol as a preservative. The administration of intravenous solutions containing the preservative benzyl alcohol has been associated with the "gasping syndrome", and death in neonates. Symptoms include a striking onset of gasping respiration, hypotension, bradycardia, and cardiovascular collapse. Although the normal therapeutic dose of this product delivers amounts of benzyl alcohol that are substantially lower than those reported in association with the "gasping syndrome", the minimum amount of benzyl alcohol at which toxicity may occur is not known and total daily benzyl alcohol exposure may be increased by concomitant medications.

The risk of benzyl alcohol toxicity depends on the quantity administered and the liver and kidneys' capacity to detoxify the chemical. Premature and low birth weight infants may be more likely to develop toxicity.

Nephrotoxicity

Clindamycin is potentially nephrotoxic and cases with acute kidney injury have been reported. Consider monitoring of renal function particularly in patients with pre-existing renal dysfunction or those taking concomitant nephrotoxic drugs. In case of acute kidney injury, discontinue CLEOCIN PHOSPHATE when no other etiology is identified.

Usage in Meningitis

Since clindamycin does not diffuse adequately into the cerebrospinal fluid, the drug should not be used in the treatment of meningitis.

PRECAUTIONS

General

Review of experience to date suggests that a subgroup of older patients with associated severe illness may tolerate diarrhea less well. When clindamycin is indicated in these patients, they should be carefully monitored for change in bowel frequency.

CLEOCIN PHOSPHATE products should be prescribed with caution in individuals with a history of gastrointestinal disease, particularly colitis.

CLEOCIN PHOSPHATE should be prescribed with caution in atopic individuals.

Certain infections may require incision and drainage or other indicated surgical procedures in addition to antibiotic therapy.

The use of CLEOCIN PHOSPHATE may result in overgrowth of nonsusceptible organisms-particularly yeasts. Should superinfections occur, appropriate measures should be taken as indicated by the clinical situation.

CLEOCIN PHOSPHATE should not be injected intravenously undiluted as a bolus, but should be infused over at least 10–60 minutes as directed in the **DOSAGE AND ADMINISTRATION** section.

Clindamycin dosage modification is not necessary in patients with renal disease. In patients with moderate to severe liver disease, prolongation of clindamycin half-life has been found. However, it was postulated from studies that when given every eight hours,

accumulation should rarely occur. Therefore, dosage modification in patients with liver disease may not be necessary. However, periodic liver enzyme determinations should be made when treating patients with severe liver disease.

Prescribing CLEOCIN PHOSPHATE in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.

Information for Patients

Patients should be counseled that antibacterial drugs including CLEOCIN PHOSPHATE should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When CLEOCIN PHOSPHATE is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by CLEOCIN PHOSPHATE or other antibacterial drugs in the future.

Diarrhea is a common problem caused by antibiotics which usually ends when the antibiotic is discontinued. Sometimes after starting treatment with antibiotics, patients can develop watery and bloody stools (with or without stomach cramps and fever) even as late as two or more months after having taken the last dose of the antibiotic. If this occurs, patients should contact their physician as soon as possible.

Laboratory Tests

During prolonged therapy periodic liver and kidney function tests and blood counts should be performed.

Drug Interactions

Clindamycin has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents. Therefore, it should be used with caution in patients receiving such agents.

Clindamycin is metabolized predominantly by CYP3A4, and to a lesser extent by CYP3A5, to the major metabolite clindamycin sulfoxide and minor metabolite Ndesmethylclindamycin. Therefore, inhibitors of CYP3A4 and CYP3A5 may increase plasma concentrations of clindamycin and inducers of these isoenzymes may reduce plasma concentrations of clindamycin. In the presence of strong CYP3A4 inhibitors, monitor for adverse reactions. In the presence of strong CYP3A4 inducers such as rifampicin, monitor for loss of effectiveness.

In vitro studies indicate that clindamycin does not inhibit CYP1A2, CYP2C9, CYP2C19, CYP2E1 or CYP2D6 and only moderately inhibits CYP3A4.

Carcinogenesis, Mutagenesis, Impairment of Fertility

Long term studies in animals have not been performed with clindamycin to evaluate carcinogenic potential. Genotoxicity tests performed included a rat micronucleus test and an Ames Salmonella reversion test. Both tests were negative.

Fertility studies in rats treated orally with up to 300 mg/kg/day (approximately 1.1 times the highest recommended adult human dose based on mg/m²) revealed no effects on fertility or mating ability.

Pregnancy

Teratogenic effects

In clinical trials with pregnant women, the systemic administration of clindamycin during the second and third trimesters, has not been associated with an increased frequency of congenital abnormalities.

Clindamycin should be used during the first trimester of pregnancy only if clearly needed. There are no adequate and well-controlled studies in pregnant women during the first trimester of pregnancy. Because animal reproduction studies are not always predictive of the human response, this drug should be used during pregnancy only if clearly needed.

Reproduction studies performed in rats and mice using oral doses of clindamycin up to 600 mg/kg/day (2.1 and 1.1 times the highest recommended adult human dose based on mg/m², respectively) or subcutaneous doses of clindamycin up to 250 mg/kg/day (0.9 and 0.5 times the highest recommended adult human dose based on mg/m², respectively) revealed no evidence of teratogenicity.

CLEOCIN PHOSPHATE Sterile Solution contains benzyl alcohol. Benzyl alcohol can cross the placenta. See **WARNINGS**.

Nursing Mothers

Limited published data based on breast milk sampling reports that clindamycin appears in human breast milk in the range of less than 0.5 to 3.8 mcg/mL at dosages of 150 mg orally to 600 mg intravenously. Clindamycin has the potential to cause adverse effects on the breast-fed infant's gastrointestinal flora. If oral or intravenous clindamycin is required by a nursing mother, it is not a reason to discontinue breastfeeding, but an alternate drug may be preferred. Monitor the breast-fed infant for possible adverse effects on the gastrointestinal flora, such as diarrhea, candidiasis (thrush, diaper rash) or rarely, blood in the stool indicating possible antibiotic-associated colitis.

The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for clindamycin and any potential adverse effects on the breast-fed child from clindamycin or from the underlying maternal condition.

Pediatric Use

When CLEOCIN PHOSPHATE Sterile Solution is administered to the pediatric population (birth to 16 years) appropriate monitoring of organ system functions is desirable (see **CLINICAL PHARMACOLOGY** and **DOSAGE AND ADMINISTRATION)**.

Usage in Newborns and Infants

This product contains benzyl alcohol as a preservative. Benzyl alcohol has been associated with a fatal "Gasping Syndrome" in premature infants. See **WARNINGS**.

The potential for the toxic effect in the pediatric population from chemicals that may

leach from the single dose premixed IV preparation in plastic has not been evaluated. See **WARNINGS**.

Geriatric Use

Clinical studies of clindamycin did not include sufficient numbers of patients age 65 and over to determine whether they respond differently from younger patients. However, other reported clinical experience indicates that antibiotic-associated colitis and diarrhea (due to *Clostridioides difficile*) seen in association with most antibiotics occur more frequently in the elderly (>60 years) and may be more severe. These patients should be carefully monitored for the development of diarrhea.

Pharmacokinetic studies with clindamycin have shown no clinically important differences between young and elderly subjects with normal hepatic function and normal (ageadjusted) renal function after oral or intravenous administration.

ADVERSE REACTIONS

The following reactions have been reported with the use of clindamycin.

Infections and Infestations: Clostridioides difficile colitis

Gastrointestinal: Antibiotic-associated colitis (see **WARNINGS**), pseudomembranous colitis, abdominal pain, nausea, and vomiting. The onset of pseudomembranous colitis symptoms may occur during or after antibacterial treatment (see **WARNINGS**). An unpleasant or metallic taste has been reported after intravenous administration of the higher doses of clindamycin phosphate.

Hypersensitivity Reactions: Maculopapular rash and urticaria have been observed during drug therapy. Generalized mild to moderate morbilliform-like skin rashes are the most frequently reported of all adverse reactions.

Severe skin reactions such as Toxic Epidermal Necrolysis, some with fatal outcome, have been reported (see **WARNINGS**). Cases of Acute Generalized Exanthematous Pustulosis (AGEP), erythema multiforme, some resembling Stevens-Johnson syndrome, have been associated with clindamycin. Anaphylactic shock, anaphylactic reaction and hypersensitivity have also been reported (see **WARNINGS**).

Skin and Mucous Membranes: Pruritus, vaginitis, angioedema and rare instances of exfoliative dermatitis have been reported (see **Hypersensitivity Reactions**).

Liver: Jaundice and abnormalities in liver function tests have been observed during clindamycin therapy.

Renal: Acute kidney injury (see WARNINGS).

Hematopoietic: Transient neutropenia (leukopenia) and eosinophilia have been reported. Reports of agranulocytosis and thrombocytopenia have been made. No direct etiologic relationship to concurrent clindamycin therapy could be made in any of the foregoing.

Immune System: Drug reaction with eosinophilia and systemic symptoms (DRESS) cases have been reported.

Local Reactions: Injection site irritation, pain, induration and sterile abscess have been

reported after intramuscular injection and thrombophlebitis after intravenous infusion. Reactions can be minimized or avoided by giving deep intramuscular injections and avoiding prolonged use of indwelling intravenous catheters.

Musculoskeletal: Polyarthritis cases have been reported.

Cardiovascular: Cardiopulmonary arrest and hypotension have been reported following too rapid intravenous administration (see **DOSAGE AND ADMINISTRATION**).

OVERDOSAGE

Significant mortality was observed in mice at an intravenous dose of 855 mg/kg and in rats at an oral or subcutaneous dose of approximately 2618 mg/kg. In the mice, convulsions and depression were observed.

Hemodialysis and peritoneal dialysis are not effective in removing clindamycin from the serum.

DOSAGE AND ADMINISTRATION

If diarrhea occurs during therapy, this antibiotic should be discontinued (see **WARNING** box).

Clindamycin phosphate IM administration should be used undiluted.

<u>Clindamycin phosphate IV administration should be diluted</u> (see **Dilution for IV use and IV infusion rates** below).

Adults

Parenteral (IM or IV Administration)

Serious infections due to aerobic gram-positive cocci and the more susceptible anaerobes (NOT generally including *Bacteroides fragilis*, *Peptococcus* species and *Clostridium* species other than *Clostridium perfringens*):

600–1200 mg/day in 2, 3 or 4 equal doses.

More severe infections, particularly those due to proven or suspected *Bacteroides fragilis, Peptococcus* species, or *Clostridium* species other than *Clostridium* perfringens:

1200-2700 mg/day in 2, 3 or 4 equal doses.

For more serious infections, these doses may have to be increased. In life-threatening situations due to either aerobes or anaerobes these doses may be increased. Doses of as much as 4800 mg daily have been given intravenously to adults (see **Dilution for IV use and IV Infusion Rates** section below).

Single intramuscular injections of greater than 600 mg are not recommended.

Alternatively, drug may be administered in the form of a single rapid infusion of the first dose followed by continuous IV infusion as follows:

Table 2: Serum Clindamycin Levels Maintained, Rapid Infusion Rate and

To maintain serum clindamycin levels	Rapid infusion rate	Maintenance infusion rate
Above	10 mg/min	0.75 mg/min
4 mcg/mL	for 30 min	_
Above	15 mg/min	1.00 mg/min
5 mcg/mL	for 30 min	-
Above	20 mg/min	1.25 mg/min
6 mcg/mL	for 30 min	-

Maintenance Infusion Rate

Pediatric Patients 1 month of age to 16 years

Parenteral (IM or IV) Administration

20 to 40 mg/kg/day in 3 or 4 equal doses. The higher doses would be used for more severe infections. Clindamycin should be dosed based on total body weight regardless of obesity. As an alternative to dosing on a body weight basis, pediatric patients may be dosed on the basis of square meters body surface: 350 mg/m²/day for serious infections and 450 mg/m²/day for more severe infections.

Parenteral therapy may be changed to oral CLEOCIN PEDIATRIC[®] Flavored Granules (clindamycin palmitate hydrochloride) or CLEOCIN HCl[®] Capsules (clindamycin hydrochloride) when the condition warrants and at the discretion of the physician.

In cases of β -hemolytic streptococcal infections, treatment should be continued for at least 10 days.

Pediatric Patients less than 1 month

The recommended dosage is 15 to 20 mg/kg/day in 3 to 4 equal doses. See Table 3 regarding the dosing regimen for pediatric patients with post-menstrual age (PMA) less than or equal to 32 weeks, or greater than 32 weeks to less than or equal to 40 weeks.

Table 3: Dosing Regimens for Pediatric Patients with PMA less than or equalto 32 weeks, or greater than 32 weeks to less than or equal to 40 weeks

PMA (weeks)	Dose (mg/kg)	Dosing Interval (hours)
Less than or equal to 32	5	8
Greater than or equal to	7	8
32 to less than or equal		
to 40		

PMA: Post-Menstrual age

Dilution for IV use and IV Infusion Rates

The concentration of clindamycin in diluent for infusion should not exceed 18 mg per mL. Infusion rates should not exceed 30 mg per minute. The usual infusion dilutions and rates are as follows:

Dose	Diluent	Time

300 mg	50 mL	10 min
600 mg	50 mL	20 min
900 mg	50–100 mL	30 min
1200 mg	100 mL	40 min

Administration of more than 1200 mg in a single 1-hour infusion is not recommended.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

Dilution and Compatibility

Physical and biological compatibility studies monitored for 24 hours at room temperature have demonstrated no inactivation or incompatibility with the use of CLEOCIN PHOSPHATE Sterile Solution (clindamycin phosphate) in IV solutions containing sodium chloride, glucose, calcium or potassium, and solutions containing vitamin B complex in concentrations usually used clinically. No incompatibility has been demonstrated with the antibiotics cephalothin, kanamycin, gentamicin, penicillin or carbenicillin.

The following drugs are physically incompatible with clindamycin phosphate: ampicillin sodium, phenytoin sodium, barbiturates, aminophylline, calcium gluconate, and magnesium sulfate.

The compatibility and duration of stability of drug admixtures will vary depending on concentration and other conditions.

Physico-Chemical Stability of Diluted Solutions of CLEOCIN PHOSPHATE

Room Temperature

6, 9 and 12 mg/mL (equivalent to clindamycin base) in dextrose injection 5%, sodium chloride injection 0.9%, or Lactated Ringers Injection in glass bottles, demonstrated physical and chemical stability for at least 16 days at 25°C.

Refrigeration

6, 9 and 12 mg/mL (equivalent to clindamycin base) in dextrose injection 5%, sodium chloride injection 0.9%, or Lactated Ringers Injection in glass bottles, demonstrated physical and chemical stability for at least 32 days at 4°C.

IMPORTANT: This chemical stability information in no way indicates that it would be acceptable practice to use this product well after the preparation time. Good professional practice suggests that compounded admixtures should be administered as soon after preparation as is feasible.

HOW SUPPLIED

Each mL of CLEOCIN PHOSPHATE Sterile Solution contains clindamycin phosphate equivalent to 150 mg clindamycin, 0.5 mg disodium edetate; 9.45 mg benzyl alcohol added as preservative. When necessary, pH is adjusted with sodium hydroxide and/or hydrochloric acid. CLEOCIN PHOSPHATE is available in the following packages:

25–2 mL vials	NDC 0009-3051-02
25-4 mL vials	NDC 0009-4073-04
25-6 mL vials	NDC 0009-5095-06

Store at controlled room temperature 20° to 25°C (68° to 77°F) [see USP].

REFERENCES

1. Smith RB, Phillips JP: Evaluation of CLEOCIN HCl and CLEOCIN Phosphate in an Aged Population. Upjohn TR 8147-82-9122-021, December 1982.

This product's labeling may have been updated. For the most recent prescribing information, please visit www.pfizer.com.

Distributed by Pharmacia & Upjohn Company LLC A subsidiary of Pfizer Inc. New York, NY 10001



Novaplus is a registered trademark of Vizient, Inc.

LAB-1388-7.0 Revised: 3/2025

PRINCIPAL DISPLAY PANEL - 2 mL Vial Label

NDC 0009-3051-01 Rx ONLY

Cleocin Phosphate[®]


clindamycin injection, USP

2 mL Vial

For intramuscular or intravenous use

novaplus™

300 mg/ 2 mL* (150 mg/mL)



PRINCIPAL DISPLAY PANEL - 2 mL Vial Carton

NDC 0009-3051-02 Contains 25 of NDC 0009-3051-01

Cleocin Phosphate[®] clindamycin injection, USP


300 mg/ 2 mL* (150 mg/mL)

25—2 mL Single Dose Vials

For intramuscular or intravenous use

Rx ONLY

novaplus™



PRINCIPAL DISPLAY PANEL - 4 mL Vial Label

NDC 0009-4073-03 Rx ONLY

Cleocin Phosphate[®]


clindamycin injection, USP

4 mL Vial

For intramuscular or intravenous use

novaplus™

600 mg/ 4 mL* (150 mg/mL)



PRINCIPAL DISPLAY PANEL - 4 mL Vial Carton

NDC 0009-4073-04 Contains 25 of NDC 0009-4073-03

Cleocin Phosphate[®] clindamycin injection, USP


600 mg/ 4 mL* (150 mg/mL)

25—4 mL Single Dose Vials

For intramuscular or intravenous use

Rx ONLY

novaplus™



PRINCIPAL DISPLAY PANEL - 6 mL Vial Label

NDC 0009-5095-05

Rx ONLY

Cleocin Phosphate[®]


clindamycin injection, USP

6 mL Vial

For intramuscular or intravenous use

novaplus™

900 mg/ 6 mL* (150 mg/mL)



PRINCIPAL DISPLAY PANEL - 6 mL Vial Carton

NDC 0009-5095-06 Contains 25 of NDC 0009-5095-05

Cleocin Phosphate[®] clindamycin injection, USP


900 mg/ 6 mL* (150 mg/mL)

25-6 mL Single Dose Vials

For intramuscular or intravenous use

Rx ONLY

novaplus™



CLEOCIN PHOSPHATE

clindamycin phosphate injection, solution

Pr	oduct Infor	mation				
Pr	oduct Type		HUMAN PRESCRIPTION DRUG	ltem	Code (Source	e) NDC:0009-30
	ute of Admini	stration	INTRAMUSCULAR, INTRAVENOUS			
		Structon				
Ac	tive Ingredi	ent/Active	Moiety			
		Ingre	dient Name		Basis o Streng	STrond 1
	INDAMYCIN PHO II:3U02EL437C)	OSPHATE (UNII:	EH6D7113I8) (CLINDAMYCIN -		CLINDAMYCIN	150 mg in 1 mL
Ina	active Ingre					
		-	redient Name			Strength
ED	ETATE DISODIU	M (UNII: 7FLD9)	1C86K)		0.5 mg i	in 1 mL
					9.45 mg	in 1 mL
so	NZYL ALCOHOL DIUM HYDROXII DROCHLORIC A	DE (UNII: 55X04	QC32I)		9.45 mg	in 1 mL
SO HY	DIUM HYDROXII DROCHLORIC A	DE (UNII: 55X04	QC32I)		9.45 mg	in 1 mL
so HY Pa	DIUM HYDROXII	DE (UNII: 55X04 CI D (UNII: QTT1	QC32I)		9.45 mg	in 1 mL Marketing En Date
so нү Ра #	DIUM HYDROXII DROCHLORIC A ICKaging	DE (UNII: 55X04 CI D (UNII: QTT1	QC32I) 7582CB) kage Description		ting Start Pate	Marketing En
so HY Pa 1	DIUM HYDROXII DROCHLORIC A Ckaging Item Code NDC:0009-3051- 02	DE (UNII: 55X04 CID (UNII: QTT1 Pac 25 in 1 CARTC	QC32I) 7582CB) kage Description	D	ting Start Pate	Marketing En
so HY Pa #	DIUM HYDROXII DROCHLORIC A Ckaging Item Code NDC:0009-3051- 02 NDC:0009-3051-	DE (UNII: 55X04 CID (UNII: QTT1 Pac 25 in 1 CARTC 2 mL in 1 VIAL	QC32I) 17582CB) S kage Description	D	ting Start Pate	Marketing En
so HY Pa 1	DIUM HYDROXII DROCHLORIC A Ckaging Item Code NDC:0009-3051- 02 NDC:0009-3051-	DE (UNII: 55X04 CID (UNII: QTT1 Pac 25 in 1 CARTC 2 mL in 1 VIAL Product	QC32I) 17582CB) :kage Description N ; Type 0: Not a Combination	D	ting Start Pate	Marketing En
so HY Pa 1	DIUM HYDROXII DROCHLORIC A Ickaging Item Code NDC:0009-3051- 02 NDC:0009-3051- 01	Pac 25 in 1 CARTC 2 mL in 1 VIAL Product	QC32I) 17582CB) :kage Description N ; Type 0: Not a Combination	D	ting Start Pate	Marketing En Date

CLEOCIN PHOSPHAT clindamycin phosphate injecti				
Product Information				
Product Type	HUMAN PRESCRIPTION DRUG	Item Co	ode (Source)	NDC:0009-4073
Route of Administration	INTRAMUSCULAR, INTRAVENOUS			
Active Ingredient/Active	Moiety			
Ingre	edient Name		Basis of Strength	Strength
CLINDAMYCIN PHOSPHATE (UNII	EH6D7113I8) (CLINDAMYCIN -	(150 mg

Inactive Ing	edients			
	Ingredient Name			Strength
EDETATE DISOD	IUM (UNII: 7FLD91C86K)		0.5 mg in	1 mL
BENZYL ALCOHO	L (UNII: LKG8494WBH)		9.45 mg i	n 1 mL
SODIUM HYDRO	(IDE (UNII: 55X04QC32I)			
IYDROCHLORIC	ACID (UNII: QTT17582CB)			
Packaging				
# Item Code	Package Description	Marketing S Date	Start	Marketing End Date
1 NDC:0009-4073	25 in 1 CARTON	11/18/2019		
1 NDC:0009-4073	4 mL in 1 VIAL; Type 0: Not a Combination Product			
Marketing	Information			
	Application Number or Monograp	h Marketin		Marketing End
Marketing Category	Citation	Dat	e	Date

CLEOCIN PHOSPHAT	E			
clindamycin phosphate injecti	on, solution			
Product Information				
Product Type	HUMAN PRESCRIPTION DRUG	ltem Co	de (Source)	NDC:0009-5095
Route of Administration	INTRAMUSCULAR, INTRAVENOUS			
Active Ingredient/Active	Moiety			
Ingre	dient Name		Basis of Strength	Strength
CLINDAMYCIN PHOSPHATE (UNII: UNII:3U02EL437C)	EH6D7113I8) (CLINDAMYCIN -	С	LINDAMYCIN	150 mg in 1 mL
Inactive Ingredients				
Ing	redient Name		Str	ength
EDETATE DISODIUM (UNII: 7FLD9:	1С86К)		0.5 mg in 1 m	L
BENZYL ALCOHOL (UNII: LKG8494	WBH)		9.45 mg in 1 r	nL
SODIUM HYDROXIDE (UNII: 55X04	QC32I)			
HYDROCHLORIC ACID (UNII: QTT1	7582CB)			

Pa	ckaging			
#	ltem Code	Package Description	Marketing Start Date	Marketing End Date
L	NDC:0009-5095- 06	25 in 1 CARTON	11/18/2019	
	NDC:0009-5095- 05	6 mL in 1 VIAL; Type 0: Not a Combination Product		
Μ	arketing l	nformation		
Μ	arketing l Marketing Category	nformation Application Number or Monograph Citation	Marketing Start Date	Marketing End Date

Labe	er - Pharmacia & Upjohn Company LLC (618054084)
------	--

Establishment				
Name	Address	ID/FEI	Business Operations	
Pharmacia & Upjohn Company LLC			ANALYSIS(0009-3051, 0009-4073, 0009-5095), MANUFACTURE(0009-3051, 0009-4073, 0009-5095), PACK(0009-3051, 0009-4073, 0009-5095), LABEL(0009-3051, 0009-4073, 0009-5095)	

Revised: 4/2025

Pharmacia & Upjohn Company LLC